Ruxolitinib treatment for myelofibrosis with anemia: a retrospective assessment of real-world patient characteristics, treatment patterns, and survival.
Saved in:
| Title: | Ruxolitinib treatment for myelofibrosis with anemia: a retrospective assessment of real-world patient characteristics, treatment patterns, and survival. |
|---|---|
| Authors: | Kuykendall AT; Moffitt Cancer Center, Tampa, FL, USA., Palandri F; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico S. Orsola-Malpighi, Istituto di Ematologia 'Seràgnoli,' Bologna, Italy., Fillbrunn M; Analysis Group, Boston, MA, USA., Liu T; GSK plc, Collegeville, PA, USA., Zhang S; GSK plc, Collegeville, PA, USA., Zhang A; Analysis Group, Boston, MA, USA., Simpson R; Analysis Group, Boston, MA, USA., Sajeev G; Analysis Group, Boston, MA, USA., Signorovitch J; Analysis Group, Boston, MA, USA., Patnaik D; GSK plc, Baar, Switzerland., Gerds AT; Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA. |
| Source: | Leukemia & lymphoma [Leuk Lymphoma] 2026 Apr; Vol. 67 (5), pp. 1088-1099. Date of Electronic Publication: 2026 Feb 27. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
